NCT02063997 - Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients | Biotech Hunter

Enrollment

248

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Gout

Interventions

DRUG

Arhalofenate 600 mg

Arhalofenate 600 mg tablets once daily for 12 weeks

DRUG

Allopurinol 300 mg

Allopurinol 300 mg tablets once daily for 12 weeks

DRUG

Colchicine 0.6 mg

Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks

DRUG

Placebo

Placebo tablets once daily for 12 weeks

DRUG

Arhalofenate 800 mg

Arhalofenate 800 mg tablets once daily for 12 weeks

Trial Locations (56)

Unknown

Birmingham

Scottsdale

Tucson

Little Rock

El Cajon

Long Beach

Los Angeles

Denver

Washington D.C.

Clearwater

DeLand

Jupiter

New Port Richey

Orlando

Palm Harbor

St. Petersburg

Tampa

Honolulu

Boise

Brownsburg

Bowling Green

Elizabethtown

Louisville

Owensboro

Hagerstown

Olive Branch

St Louis

Missoula

Omaha

Brooklyn

New York

Charlotte

Greensboro

Hickory

Raleigh

Salisbury

Winston-Salem

Cincinnati

Oklahoma City

Portland

Johnstown

Wyomissing

Charleston

Greer

Summerville

Bristol

Jackson

Houston

Salt Lake City

West Jordan

Spokane

Clarksburg

Newmarket

Sarnia

Toronto

Tbilisi